Brought to you by 
BMS licenses cancer MAbs to start-up Seattle Genetics
13 Jul 1999
Executive Summary
Bristol-Myers Squibb has licensed its cancer MAbs consisting of tumor targeting compounds and technology to start-up Seattle Genetics (spin-off of BMS's former molecular immunology program).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com